Ontvang nu dagelijks onze kooptips!
word abonnee
sluiten ✕
Terug naar discussie overzicht
Degroof Petercam 7 augustus 2020Galapagos (Buy from Hold) - 2Q20 results (EUR 158.5 / TP EUR 205 from EUR 223) Facts Revenues amounted to EUR 118m (Css. EUR 113m; DPe EUR 120m). OPEX increased 82% YoY, landing at EUR 204m (Css. EUR 172m; DPe EUR 182m), comprising EUR 149m in R&D, EUR 17m in S&M and EUR 38m in G&A. The company realized a net loss of EUR 86m (Css. EUR 93m net loss; DPe EUR 71m net loss). Cash & cash equivalents end of June stood at EUR 5,566m (Css. EUR 5,575m; DPe EUR 5,669m). The FY20 operational cash burn guidance of EUR 400m – EUR 430m was reiterated. After a pause in recruitment due to COVID-19 in DIVERSITY and PENGUIN - the ongoing filgotinib trials in Crohn’s disease and psoriatic arthritis - Gilead recently restarted recruiting patients at select sites, and enrollment into the MANTA and MANTA-RAy studies has been concluded.Outlook for second semester of 2020: Filgotinib: 1/ rheumatoid arthritis: following positive CHMP opinion, potential approval is anticipated 2/ ankylosing spondylitis: Phase III launch GLPG1972 (collaboration with Servier): Phase IIb topline in osteoarthritis (OA) GLPG1205: PINTA Phase II topline in idiopathic pulmonary fibrosis (IPF) GLPG1690 (ziritaxestat): NOVESA Phase IIa topline in systemic sclerosis (SSc) Toledo: launch of `3970 exploratory Phase II trials with anticipated readout 1H21 The company is hosting a conference call today at 14:00 CET. Our view – Steep increase in OPEX YoY We observe a steep increase in OPEX YoY. Based on the latter, we took the liberty to factor in a higher of level of future OPEX projections to better reflect the company’s anticipated transition into a biopharmaceutical entity as well as the higher level overhead costs due to a continuously expanding (pre)clinical R&D efforts. Expected newsflow for 2020 remains on track: The most significant milestone will be the regulatory feedback on filgotinib for treatment of moderate-to-severe rheumatoid arthritis (RA) expected in the upcoming months. Based on the solid Phase III data package, our model assumes approval and potential peak sales of EUR 3,361m. GLPG1972: our 50% success rate in OA is relatively bullish and to a large extent implies a positive outcome of the ongoing Phase IIb trial. Both GLPG1205 and ziritaxestat being evaluated in exploratory Phase IIa trials in IPF and SSc, respectively, we consider the most substantial value-inflection for these indications to occur after positive readout in larger, qualitative follow-up trials.Investment conclusion We value Galapagos using an rNPV (WACC: 11%). After adjusting OPEX projections, cash position and outstanding shares, our PT arrives at EUR 205. We acknowledge that our SOTP valuation might pose some downside risk, given our relatively high success rate attribution to mid-to-late-stage programs. However, GLPG shares dropped substantially the past couple of months, what we consider to be an overreaction by the market, driven by Covid-19-related share price volatility and the Phase III readout of filgotinib in ulcerative colitis (UC). The latter was not perfect but still competitive with other JAKi’s being evaluated/approved in UC in our view. At current, lowered share price levels, we believe the long-term upside potential outweighs the downside risk. This is further supported by the company’s strong cash position, providing financial firepower to feed the development of (pre)clinical assets we currently do not yet include in our SOTP. We therefore upgrade to Buy.
H.C.Wainwright&CO 10 augustus 2020 Rating: Buy; Price Target: $270.002Q20 Update; Looking Beyond Filgotinib to Other Pipeline Readouts During 2H20
En terwijl de afslachting van het aandeel Galapagos gewoon door gaat knalt ook Barclays er een koopadviesje tegen aan. Maakt niks uit, dalen doet 't toch wel........ Zucht, vriendelijke groet Broer Konijn ===== Analistenadviezen DATUM ANALIST ADVIES KOERSDOEL10:31 Barclays Capital kopen 210,00 10:31 H.C. Wainwright & Co. kopen 0,00 09:32 KBC Securities houden 192,00
In elk geval fijn dat er weer koopadviezen doorsijpelen.
Mooi terras zeg ! De moeite.
Uit het augustus draadje van Anton080. Mvg Broer Konijn === Anton8080 schreef op 11 augustus 2020 09:55: (ABM FN-Dow Jones) Barclays heeft het koersdoel voor Galapagos verlaagd van 235,00 naar 210,00 euro, bij een ongewijzigd Overwogen advies. Dit bleek dinsdag uit een analistenrapport van de zakenbank. Het koersdoel werd verlaagd vanwege de hogere operationele kosten die de Britse bank voorziet. ?Het advies bleef gehandhaafd op Overwogen vanwege de aanhoudende vooruitgang met filgotinib in de VS. Volgens de analisten bevatten de recente kwartaalcijfers en de daaropvolgende toelichting door Galapagos weinig nieuwe informatie, wat de bank als positief beschouwt. “Het is een nare zomer voor het aandeel Galapagos,” concludeerden de analisten van Barclays. Het aandeel doet het sinds de publicatie eind mei van SELECTION-data duidelijk minder goed dan sectorgenoten. Het aandeel Galapagos steeg dinsdag 2,5 procent tot 158,70 euro. Door: ABM Financial News.info@abmfn.nl Redactie: +31(0)20 26 28 999
Van IEX. Mvg Broer Konijn === Morgan Stanley herhaalt het houdadvies voor Galapagos maandag 17 augustus 2020 - 08:58u - Morgan Stanley herhaalt het houdadvies van 11 aug 2020 voor Galapagos. Het houdadvies van dinsdag 11 augustus 2020 wordt herhaald. Dit vorige advies heeft geresulteerd in een rendement van 1,03%. Fonds: Galapagos Guru: Morgan Stanley Advies: Houden Status: Actief Koersdoel: - Score: 0,00% Startkoers: € 157,95 Huidige koers: € 157,10 Verw. rendement: - 17 augustus 2020 - 12:04u
Extract Morgan Stanley 19 augustus 2020Filgotinib CRL A Surprise; Male Reproductive Toxicity Study and 200mg risk/benefit Key Issues North America Industry View In-Line Matthew Harrison, Connor Meehan, Thomas F Lavery, J.D. August 19, 2020 FDA does not approve filgotinib citing need for MANTA data (due in 1H21) and risk/benefit with 200mg dose: FDA has requested data from the MANTA and MANTA-RAy trials, both of which are fully recruited and ongoing, and are intended to evaluate filgotinib's effect on reproductive health in male participants. Mgt. expects to report topline results from the MANTA and MANTA-RAy studies in 1H21 (we believe the 26 week data is likely required for re-filing and could be available in early 2021). The FDA also cited a second issue, unrelated to MANTA, concerning the risk/benefit of the 200mg dose. Review is ongoing in Japan, and mgt. expects a response from Japanese regulators by YE20. As a reminder, filgotinib received a positive opinion from CHMP (Committee for Medicinal Products for Human Use) at both dose levels in July (note here). Galapagos is due $75M on approval in the EU and $30M on Japan approval. Galapagos has increased its cash burn by $100M to account for the lack of the US approval milestone from Gilead. As summarized in our prior scenario analysis, available here, we see GLPG down 10%+ (~20% of EV) and GILD down 3%+ as a result of these events. We spoke with both Gilead and Galapagos. Key takeaways include: (1) Mgt. has provided FDA with blinded interim data from the MANTA studies, but FDA indicated it needs the complete unblinded data to evaluate filgotinib; (2 ) On the 200mg dose, mgt. characterized the issue as relating to the overall safety profile versus 100mg. Mgt. indicated that FDA was not focused on any specific safety imbalance. Further mgt. indicated that there was not a 'surprise' event in the safety database which caused FDA concern, rather the FDA concern is similar to the scrutiny higher doses of other JAK inhibitors faced. Mgt. does not see a read-through to potential approval of 200mg in UC given different divisions evaluate the drug; (3) Mgt. will have add'l safety follow-up from DARWIN3 and FINCH4 which could be used to better characterize the safety profile of 200mg for refiling; (4) Gilead mgt. acknowledged that the 200mg dose is important to the commercial profile of filgotinib in a very crowded class and that it may have to re-evaluate its filgotinib strategy if it cannot receive approval for the 200mg dose in RA. Mgt. highlighted that it will be disciplined with its commercial investment; (5) Mgt. will request a meeting with the FDA in the near-term to more clearly understand FDA's concerns and what data is needed to refile. Currently mgt. would anticipate refiling after MANTA data is available, but can't confirm a specific timeline until meeting with FDA (i.e., FDA could ask for longer than 26 weeks of follow-up from MANTA/RAy).
Extract Jefferies mbt Gilead Filgotinib CRL A Surprise; Male Reproductive Toxicity Study and 200mg risk/benefit Key Issues Michael Lee August 19, 2020 Gilead Sciences, Inc. (GILD) BUY, $69.06 PT: $78.00 CRL for filgotinib is a setback given it was a key growth driver and $2B+ peak consensus. On the other side, we don't think expectations were super high for GILD against leader ABBV anyway and we've been saying there was some risk around 200mg high dose all along in reports/videos. We predict GILD will await more safety data in H1-21 but ultimately GILD could make tough decisions on FILG and will continue to increase focus on oncology (5 deals this year). FDA does not approve filgotinib citing need for MANTA data (due in 1H21) and risk/benefit with 200mg dose: FDA has requested data from the MANTA and MANTA-RAy trials, both of which are fully recruited and ongoing, and are intended to evaluate filgotinib's effect on reproductive health in male participants. Mgt. expects to report topline results from the MANTA and MANTA-RAy studies in 1H21 (we believe the 26 week data is likely required for re-filing and could be available in early 2021). The FDA also cited a second issue, unrelated to MANTA, concerning the risk/benefit of the 200mg dose. Review is ongoing in Japan, and mgt. expects a response from Japanese regulators by YE20. As a reminder, filgotinib received a positive opinion from CHMP (Committee for Medicinal Products for Human Use) at both dose levels in July (note here). Galapagos is due $75M on approval in the EU and $30M on Japan approval. Galapagos has increased its cash burn by $100M to account for the lack of the US approval milestone from Gilead. As summarized in our prior scenario analysis, available here, we see GLPG down 10%+ (~20% of EV) and GILD down 3%+ as a result of these events. We spoke with both Gilead and Galapagos. Key takeaways include: (1) Mgt. has provided FDA with blinded interim data from the MANTA studies, but FDA indicated it needs the complete unblinded data to evaluate filgotinib; (2) On the 200mg dose, mgt. characterized the issue as relating to the overall safety profile versus 100mg. Mgt. indicated that FDA was not focused on any specific safety imbalance. Further mgt. indicated that there was not a 'surprise' event in the safety database which caused FDA concern, rather the FDA concern is similar to the scrutiny higher doses of other JAK inhibitors faced. Mgt. does not see a read-through to potential approval of 200mg in UC given different divisions evaluate the drug; (3) Mgt. will have add'l safety follow-up from DARWIN3 and FINCH4 which could be used to better characterize the safety profile of 200mg for refiling; (4) Gilead mgt. acknowledged that the 200mg dose is important to the commercial profile of filgotinib in a very crowded class and that it may have to re-evaluate its filgotinib strategy if it cannot receive approval for the 200mg dose in RA. Mgt. highlighted that it will be disciplined with its commercial investment; (5) Mgt. will request a meeting with the FDA in the near-term to more clearly understand FDA's concerns and what data is needed to refile. Currently mgt. would anticipate refiling after MANTA data is available, but can't confirm a specific timeline until meeting with FDA (i.e., FDA could ask for longer than 26 weeks of follow-up from MANTA/RAy).
Avantiavanti, is bovenstaand extract van Morgan Stanley of Jefferies? Blijkbaar Morgan Stanley, want Matthew Harrison zit daar.
Stifel 18 augustus 2020 Lowering Target Price To $155 On Filgotinib CRL; Calls Into Question Its Potential Differentiation Within The JAK Class
Lama Daila schreef op 19 augustus 2020 08:02 :
Avantiavanti, is bovenstaand extract van Morgan Stanley of Jefferies?
Blijkbaar Morgan Stanley, want Matthew Harrison zit daar.
Goed gezien, gecorrigeerd
avantiavanti schreef op 19 augustus 2020 08:09 :
[...]
Goed gezien, gecorrigeerd
Bedankt, maar nu nog 2 identieke alinea’s en zelfde titel in beide posts. Een cut&paste-foutje ?
Lama Daila schreef op 19 augustus 2020 08:17 :
[...]
Bedankt, maar nu nog 2 identieke alinea’s en zelfde titel in beide posts. Een cut&paste-foutje ?
Dank Lama Daila, idd copy paste foutje. Sorry all. Hierbij de file met de volledige update van Jefferies mbt Gilead.
Bryan Garnier & Co Galapagos (Buy) PT EUR 175 FV reduced to EUR175 but we are reiterating BUY ratingWe are reducing our FV from EUR215 to EUR175 Highly surprising move from the FDA as Filgotinib receives CRLKind of worst case scenario for filgotinib in the US Yesterday evening, Galapagos and its partner Gilead have announced that they have received a complete response letter (CRL) from the US FDA for filgotinib’s NDA. FDA is indeed requesting data from the safety studies MANTA and MANTA-RAy studies before completing its review of the NDA while raising concerns regarding the overall benefit/risk profile of the filgotinib 200mg dose. We see this development as all the more surprising considering that that the CHMP has just adopted a positive opinion for both two doses of filgotinib. On top of that we clearly understood in the past that full findings from those studies were not necessary for approval. We were expecting that they would have been submitted once completed as a post-approval requirement. Regarding the 200mg, we previously acknowledge that there was a risk that FDA would take a conservative approach and approve only the lower dose. We do believe that FDA concerns on the highest dose are potentially driven by testicular toxicity seen in earlier trials, and that positive results from both MANTA and MANTA-RAy will allow both doses to be approved. This current situation is definitely our worst case scenario for filgotinib in the US.
@ avantiavanti Can you post the KEMPEN Report what was released today? Preferably the full pfd report. Thanks in advance ;-)
Citi 19 augustus 2020 Galapagos (GLPG.AS)Likely 2-Year Delay for US Filgotinib Changes Prospects. Market Reaction Overdone. Buy. Upgrade to Buy (High Risk) with PT €145 – corresponding to our revised SOTP valuation (Figure 2). We adjust our filgotinib 2025e sales in RA to €2bn from €3bn and total sales to €4bn from €6bn. Although we accept that filgotinib prospects in the US have changed, with almost guaranteed European approval and €80+ per share in cash, we believe the negative market reaction is overdone and we like the risk/reward at the current level.
@Avantiavanti, wederom enorm grote dank voor het posten van rapporten hier!! AB! Ik, grotendeels stille lezer, heb hier enorm veel aan gehad gedurende afgelopen jaren en zo vast velen met mij.
avantiavanti schreef op 20 augustus 2020 16:58 :
Citi 19 augustus 2020
Galapagos (GLPG.AS)
Likely 2-Year Delay for US Filgotinib Changes Prospects. Market Reaction Overdone. Buy. Upgrade to Buy (High Risk) with PT €145 – corresponding to our revised SOTP
valuation (Figure 2). We adjust our filgotinib 2025e sales in RA to €2bn from €3bn
and total sales to €4bn from €6bn. Although we accept that filgotinib prospects in the
US have changed, with almost guaranteed European approval and €80+ per share
in cash, we believe the negative market reaction is overdone and we like the
risk/reward at the current level.
Dank voor het plaatsen! Weet iemand of en zo ja welke van onderstaand gearceerde updates we eventueel nog in dit derde kwartaal kunnen verwachten? Approval and launch of filgotinib (Europe)GLPG1972 Phase 2b data in OA (ROCCELLA) Phase 2 PINTA trial data (GLPG1205 in IPF) Potential NOVESA data from GLPG1690 in Systemic Sclerosis R&D Day likely in 4Q20 - TOLEDO mechanism disclosed
Aantal posts per pagina:
20
50
100
Direct naar Forum
-- Selecteer een forum --
Koffiekamer
Belastingzaken
Beleggingsfondsen
Beursspel
BioPharma
Daytraders
Garantieproducten
Opties
Technische Analyse
Technische Analyse Software
Vastgoed
Warrants
10 van Tak
4Energy Invest
Aalberts
AB InBev
Abionyx Pharma
Ablynx
ABN AMRO
ABO-Group
Acacia Pharma
Accell Group
Accentis
Accsys Technologies
ACCSYS TECHNOLOGIES PLC
Ackermans & van Haaren
ADMA Biologics
Adomos
AdUX
Adyen
Aedifica
Aegon
AFC Ajax
Affimed NV
ageas
Agfa-Gevaert
Ahold
Air France - KLM
Airspray
Akka Technologies
AkzoNobel
Alfen
Allfunds Group
Allfunds Group
Almunda Professionals (vh Novisource)
Alpha Pro Tech
Alphabet Inc.
Altice
Alumexx ((Voorheen Phelix (voorheen Inverko))
AM
Amarin Corporation
Amerikaanse aandelen
AMG
AMS
Amsterdam Commodities
AMT Holding
Anavex Life Sciences Corp
Antonov
Aperam
Apollo Alternative Assets
Apple
Arcadis
Arcelor Mittal
Archos
Arcona Property Fund
arGEN-X
Aroundtown SA
Arrowhead Research
Ascencio
ASIT biotech
ASMI
ASML
ASR Nederland
ATAI Life Sciences
Atenor Group
Athlon Group
Atrium European Real Estate
Auplata
Avantium
Axsome Therapeutics
Azelis Group
Azerion
B&S Group
Baan
Ballast Nedam
BALTA GROUP N.V.
BAM Groep
Banco de Sabadell
Banimmo A
Barco
Barrick Gold
BASF SE
Basic-Fit
Basilix
Batenburg Beheer
BE Semiconductor
Beaulieulaan
Befimmo
Bekaert
Belgische aandelen
Beluga
Beter Bed
Bever
Binck
Biocartis
Biophytis
Biosynex
Biotalys
Bitcoin en andere cryptocurrencies
bluebird bio
Blydenstijn-Willink
BMW
BNP Paribas S.A.
Boeing Company
Bols (Lucas Bols N.V.)
Bone Therapeutics
Borr Drilling
Boskalis
BP PLC
bpost
Brand Funding
Brederode
Brill
Bristol-Myers Squibb
Brunel
C/Tac
Campine
Canadese aandelen
Care Property Invest
Carmila
Carrefour
Cate, ten
CECONOMY
Celyad
CFD's
CFE
CGG
Chinese aandelen
Cibox Interactive
Citygroup
Claranova
CM.com
Co.Br.Ha.
Coca-Cola European Partners
Cofinimmo
Cognosec
Colruyt
Commerzbank
Compagnie des Alpes
Compagnie du Bois Sauvage
Connect Group
Continental AG
Corbion
Core Labs
Corporate Express
Corus
Crescent (voorheen Option)
Crown van Gelder
Crucell
CTP
Curetis
CV-meter
Cyber Security 1 AB
Cybergun
D'Ieteren
D.E Master Blenders 1753
Deceuninck
Delta Lloyd
DEME
Deutsche Cannabis
DEUTSCHE POST AG
Dexia
DGB Group
DIA
Diegem Kennedy
Distri-Land Certificate
DNC
Dockwise
DPA Flex Group
Draka Holding
DSC2
DSM
Duitse aandelen
Dutch Star Companies ONE
Duurzaam Beleggen
DVRG
Ease2pay
Ebusco
Eckert-Ziegler
Econocom Group
Econosto
Edelmetalen
Ekopak
Elastic N.V.
Elia
Endemol
Energie
Energiekontor
Engie
Envipco
Erasmus Beursspel
Eriks
Esperite (voorheen Cryo Save)
EUR/USD
Eurobio
Eurocastle
Eurocommercial Properties
Euronav
Euronext
Euronext
Euronext.liffe Optiecompetitie
Europcar Mobility Group
Europlasma
EVC
EVS Broadcast Equipment
Exact
Exmar
Exor
Facebook
Fagron
Fastned
Fingerprint Cards AB
First Solar Inc
FlatexDeGiro
Floridienne
Flow Traders
Fluxys Belgium D
FNG (voorheen DICO International)
Fondsmanager Gezocht
ForFarmers
Fountain
Frans Maas
Franse aandelen
FuelCell Energy
Fugro
Futures
FX, Forex, foreign exchange market, valutamarkt
Galapagos
Gamma
Gaussin
GBL
Gemalto
General Electric
Genfit
Genmab
GeoJunxion
Getronics
Gilead Sciences
Gimv
Global Graphics
Goud
GrandVision
Great Panther Mining
Greenyard
Grolsch
Grondstoffen
Grontmij
Guru
Hagemeyer
HAL
Hamon Groep
Hedge funds: Haaien of helden?
Heijmans
Heineken
Hello Fresh
HES Beheer
Hitt
Holland Colours
Homburg Invest
Home Invest Belgium
Hoop Effektenbank, v.d.
Hunter Douglas
Hydratec Industries (v/h Nyloplast)
HyGear (NPEX effectenbeurs)
HYLORIS
Hypotheken
IBA
ICT Automatisering
Iep Invest (voorheen Punch International)
Ierse aandelen
IEX Group
IEX.nl Sparen
IMCD
Immo Moury
Immobel
Imtech
ING Groep
Innoconcepts
InPost
Insmed Incorporated (INSM)
IntegraGen
Intel
Intertrust
Intervest Offices & Warehouses
Intrasense
InVivo Therapeutics Holdings Corp (NVIV)
Isotis
JDE PEET'S
Jensen-Group
Jetix Europe
Johnson & Johnson
Just Eat Takeaway
Kardan
Kas Bank
KBC Ancora
KBC Groep
Kendrion
Keyware Technologies
Kiadis Pharma
Kinepolis Group
KKO International
Klépierre
KPN
KPNQwest
KUKA AG
La Jolla Pharmaceutical
Lavide Holding (voorheen Qurius)
LBC
LBI International
Leasinvest
Logica
Lotus Bakeries
Macintosh Retail Group
Majorel
Marel
Mastrad
Materialise NV
McGregor
MDxHealth
Mediq
Melexis
Merus Labs International
Merus NV
Microsoft
Miko
Mithra Pharmaceuticals
Montea
Moolen, van der
Mopoli
Morefield Group
Mota-Engil Africa
MotorK
Moury Construct
MTY Holdings (voorheen Alanheri)
Nationale Bank van België
Nationale Nederlanden
NBZ
Nedap
Nedfield
Nedschroef
Nedsense Enterpr
Nel ASA
Neoen SA
Neopost
Neovacs
NEPI Rockcastle
Netflix
New Sources Energy
Neways Electronics
NewTree
NexTech AR Solutions
NIBC
Nieuwe Steen Investments
Nintendo
Nokia
Nokia OYJ
Nokia Oyj
Novacyt
NOVO-NORDISK AS
NPEX
NR21
Numico
Nutreco
Nvidia
NWE Nederlandse AM Hypotheek Bank
NX Filtration
NXP Semiconductors NV
Nyrstar
Nyxoah
Océ
OCI
Octoplus
Oil States International
Onconova Therapeutics
Ontex
Onward Medical
Onxeo SA
OpenTV
OpGen
Opinies - Tilburg Trading Club
Opportunty Investment Management
Orange Belgium
Oranjewoud
Ordina Beheer
Oud ForFarmers
Oxurion (vh ThromboGenics)
P&O Nedlloyd
PAVmed
Payton Planar Magnetics
Perpetuals, Steepeners
Pershing Square Holdings Ltd
Personalized Nursing Services
Pfizer
Pharco
Pharming
Pharnext
Philips
Picanol
Pieris Pharmaceuticals
Plug Power
Politiek
Porceleyne Fles
Portugese aandelen
PostNL
Priority Telecom
Prologis Euro Prop
ProQR Therapeutics
PROSIEBENSAT.1 MEDIA SE
Prosus
Proximus
Qrf
Qualcomm
Quest For Growth
Rabobank Certificaat
Randstad
Range Beleggen
Recticel
Reed Elsevier
Reesink
Refresco Gerber
Reibel
Relief therapeutics
Renewi
Rente en valuta
Resilux
Retail Estates
RoodMicrotec
Roularta Media
Royal Bank Of Scotland
Royal Dutch Shell
RTL Group
RTL Group
S&P 500
Samas Groep
Sapec
SBM Offshore
Scandinavische (Noorse, Zweedse, Deense, Finse) aandelen
Schuitema
Seagull
Sequana Medical
Shurgard
Siemens Gamesa
Sif Holding
Signify
Simac
Sioen Industries
Sipef
Sligro Food Group
SMA Solar technology
Smartphoto Group
Smit Internationale
Snowworld
SNS Fundcoach Beleggingsfondsen Competitie
SNS Reaal
SNS Small & Midcap Competitie
Sofina
Softimat
Solocal Group
Solvac
Solvay
Sopheon
Spadel
Sparen voor later
Spectra7 Microsystems
Spotify
Spyker N.V.
Stellantis
Stellantis
Stern
Stork
Sucraf A en B
Sunrun
Super de Boer
SVK (Scheerders van Kerchove)
Syensqo
Systeem Trading
Taiwan Semiconductor Manufacturing Company (TSMC)
Technicolor
Tele Atlas
Telegraaf Media
Telenet Groep Holding
Tencent Holdings Ltd
Tesla Motors Inc.
Tessenderlo Group
Tetragon Financial Group
Teva Pharmaceutical Industries
Texaf
Theon International
TherapeuticsMD
Thunderbird Resorts
TIE
Tigenix
Tikkurila
TINC
TITAN CEMENT INTERNATIONAL
TKH Group
TMC
TNT Express
TomTom
Transocean
Trigano
Tubize
Turbo's
Twilio
UCB
Umicore
Unibail-Rodamco
Unifiedpost
Unilever
Unilever
uniQure
Unit 4 Agresso
Univar
Universal Music Group
USG People
Vallourec
Value8
Value8 Cum Pref
Van de Velde
Van Lanschot
Vastned
Vastned Retail Belgium
Vedior
VendexKBB
VEON
Vermogensbeheer
Versatel
VESTAS WIND SYSTEMS
VGP
Via Net.Works
Viohalco
Vivendi
Vivoryon Therapeutics
VNU
VolkerWessels
Volkswagen
Volta Finance
Vonovia
Vopak
Warehouses
Wave Life Sciences Ltd
Wavin
WDP
Wegener
Weibo Corp
Wereldhave
Wereldhave Belgium
Wessanen
What's Cooking
Wolters Kluwer
X-FAB
Xebec
Xeikon
Xior
Yatra Capital Limited
Zalando
Zenitel
Zénobe Gramme
Ziggo
Zilver - Silver World Spot (USD)